Insights into polypharmacology from drug-domain associations

MOTIVATION Polypharmacology (the ability of a single drug to affect multiple targets) is a key feature that may explain part of the decreasing success of conventional drug discovery strategies driven by the quest for drugs to act selectively on a single target. Most drug targets are proteins that are composed of domains (their structural and functional building blocks). RESULTS In this work, we model drug-domain networks to explore the role of protein domains as drug targets and to explain drug polypharmacology in terms of the interactions between drugs and protein domains. We find that drugs are organized around a privileged set of druggable domains. CONCLUSIONS Protein domains are a good proxy for drug targets, and drug polypharmacology emerges as a consequence of the multi-domain composition of proteins. CONTACT amoyag@uma.es SUPPLEMENTARY INFORMATION Supplementary data are available at Bioinformatics online.

[1]  Rodrigo Lopez,et al.  Clustal W and Clustal X version 2.0 , 2007, Bioinform..

[2]  A. Barabasi,et al.  The human disease network , 2007, Proceedings of the National Academy of Sciences.

[3]  Damian Smedley,et al.  BioMart Central Portal: an open database network for the biological community , 2011, Database J. Biol. Databases Curation.

[4]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[5]  Sailu Yellaboina,et al.  DOMINE: a comprehensive collection of known and predicted domain-domain interactions , 2010, Nucleic Acids Res..

[6]  Robin Palotai,et al.  Community Landscapes: An Integrative Approach to Determine Overlapping Network Module Hierarchy, Identify Key Nodes and Predict Network Dynamics , 2009, PloS one.

[7]  Robert B. Russell,et al.  SuperTarget and Matador: resources for exploring drug-target relationships , 2007, Nucleic Acids Res..

[8]  Erli Pang,et al.  Promiscuous domains: facilitating stability of the yeast protein-protein interaction network. , 2012, Molecular bioSystems.

[9]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[10]  E. Koonin,et al.  The structure of the protein universe and genome evolution , 2002, Nature.

[11]  R. Solé,et al.  Data completeness—the Achilles heel of drug-target networks , 2008, Nature Biotechnology.

[12]  A. Hopkins.  Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[13]  P. Aloy,et al.  A network medicine approach to human disease , 2009, FEBS letters.

[14]  L. Holm,et al.  The Pfam protein families database , 2005, Nucleic Acids Res..

[15]  E. Birney,et al.  Pfam: the protein families database , 2013, Nucleic Acids Res..

[16]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[17]  M. DePamphilis,et al.  HUMAN DISEASE , 1957, The Ulster Medical Journal.

[18]  R. Solé,et al.  The topology of drug-target interaction networks: implicit dependence on drug properties and target families. , 2009, Molecular bioSystems.

[19]  Xing-Ming Zhao,et al.  Predicting drug targets based on protein domains. , 2012, Molecular bioSystems.

[20]  David C. Jones,et al.  CATH--a hierarchic classification of protein domain structures. , 1997, Structure.

[21]  E V Koonin,et al.  Estimating the number of protein folds and families from complete genome data. , 2000, Journal of molecular biology.

[22]  J. Nacher,et al.  Modularity in Protein Complex and Drug Interactions Reveals New Polypharmacological Properties , 2012, PloS one.

[23]  Christian von Mering,et al.  STITCH: interaction networks of chemicals and proteins , 2007, Nucleic Acids Res..

[24]  S. Lampel,et al.  The druggable genome: an update. , 2005, Drug discovery today.

[25]  Sarah A. Teichmann,et al.  Protein domain organisation: adding order , 2009, BMC Bioinformatics.